There were no clinically significant predictors of therapy response, and therapeutic alternatives were restricted. For 108 SCLCs, clinical data and somatic mutations of MSK-IMPACT panel genes were collected from cBioPortal and examined to discover mutated gene networks. The outcomes were confirmed in a separate cohort of 54 SCLCs, whose data was obtained via cBioPortal. Short and long survivors’ tumors showed different networks. The degree (K) and betweenness (B) of a gene in its linked mutation network are important characteristics. About 2 fingerprints of mutant genes were found by comparing their B/K ratios, identifying short (IL-7R, NTRK2, HNF-1A) and long survivors (NBN, PTPN-11, IRS-1, INPP-4A, PIK-3CG, HGF, LATS-2, SMARCA-4, FLT-3, EIF-4A2, SPEN, PAX-5, SH2-D1A, ARID-1A, HOXB-13, ERCC-4, FANCA, FH, FGFR-2, MST-1R, SMAD-4, DDR-2, IGF-1R, PIK-3CB). Patients with at least one mutant gene in the brief signature had a lower median overall survival of 8 months than 28 months (P<0.001). Patients with at least one altered gene in the long signature had a greater overall survival rate of 39 months than 20 months (P=0.004). The brief signature’s worth was also confirmed in a separate group of SCLCs. The mutant genes network may be used to subclassify SCLCs based on somatic mutations and identify a subpopulation of tumors with a bad prognosis.

Source:www.clinical-lung-cancer.com/article/S1525-7304(22)00108-5/fulltext